

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/GB05/000713

International filing date: 25 February 2005 (25.02.2005)

Document type: Certified copy of priority document

Document details: Country/Office: GB  
Number: 0404656.1  
Filing date: 02 March 2004 (02.03.2004)

Date of receipt at the International Bureau: 26 April 2005 (26.04.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse



GB05/713



INVESTOR IN PEOPLE

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

I also certify that the application is now proceeding in the name as identified herein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated 22 March 2005






GB 0404656.1

By virtue of a direction given under Section 30 of the Patents Act 1977, the application is proceeding in the name of:

THE UNIVERSITY OF MANCHESTER,  
Oxford Road,  
MANCHESTER,  
M13 9PL,  
United Kingdom

[ADP No. 07792138001]





**The  
Patent  
Office**

03MAR04 0977590-1 000354  
P01/7700 0.00-0404656.1 CHEQUE

## Request for grant of a patent

(see the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road  
Newport  
Gwent NP9 1RH

1.	Your reference	PCB/P089569PGB		
2.	Patent application number (The Patent Office will fill in this part)	02 MAR 2004	0404656.1	
3.	Full name, address and postcode of the or of each applicant ( <i>underline all surnames</i> )	THE VICTORIA UNIVERSITY OF MANCHESTER OXFORD ROAD MANCHESTER M13 9PL		
	Patents ADP number ( <i>if you know it</i> )	00773937001		
	If the applicant is a corporate body, give the country/state of its incorporation	UNITED KINGDOM		
4.	Title of the invention	TREATMENT OF SPINAL CONDITIONS		
5.	Name of your agent ( <i>if you have one</i> )	Marks & Clerk		
	"Address for service" in the United Kingdom to which all correspondence should be sent ( <i>including the postcode</i> )	43 Park Place Leeds LS1 2RY		
	Patents ADP number ( <i>if you know it</i> )	18013 ✓		
6.	If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and ( <i>if you know it</i> ) the or each application number	Country	Priority application number ( <i>if you know it</i> )	Date of filing ( <i>day/month/year</i> )
7.	If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application	Date of filing ( <i>day/month/year</i> )	
8.	Is a statement of Inventorship and of right to grant of a patent required in support of this request? ( <i>Answer 'Yes' if:</i> a) any applicant named in part 3 is not an inventor, or b) there is an inventor who is not named as an applicant, or c) any named applicant is a corporate body. See note (d))	YES		

# Patents Form 1/77


9. Enter the number of sheets for any of the following items you are filing with this form.  
Do not count copies of the same document

Continuation sheets of this form	-
Description	23
Claim(s)	3
Abstract	-
Drawing(s)	10 x 10 ✓

10. If you are also filing any of the following, state how many against each item.

Priority documents	-
Translations of priority documents	-
Statement of Inventorship and right to grant of a patent (Patents Form 7/77)	-
Request for preliminary examination and search (Patents Form 9/77)	1
Request for substantive examination (Patents Form 10/77)	-
Any other documents (Please specify)	-

11. I/We request the grant of a patent on the basis of this application.

Signature		Date
MARKS & CLERK		01/03/04

12. Name and daytime telephone number of person to contact in the United Kingdom

DR P. C. BANFORD – 0113 3895606

## Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

## Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.



## TREATMENT OF SPINAL CONDITIONS

The present invention relates to the treatment of spinal conditions characterized by a degeneration of the intervertebral disc (DIVD).

DIVD is believed to be caused by a loss or change in matrix production of the intervertebral disc (IVD). DIVD may arise as a consequence of age-related changes of the IVD, spondylolysis etc.

One example of a spinal condition according to the invention is low back pain (LBP). LBP is multifactorial. However it is believed that DIVD is a very common cause of LBP. About 11 million people in the UK experience LBP for at least 1 week each month; it leads to considerable loss of working days (108 million in 2000, and an estimated £11 billion in lost production). It also impacts significantly on the National Health Service (e.g. >6 million clinical consultations/annum) and social services. Although there are many causes of LBP, the role of DIVD in LBP is becoming clearer. Imaging studies indicate a link between DIVD *per se* and LBP. Furthermore the inventors of the application in suit have shown how they are linked mechanistically through nociceptive nerve ingrowth into degenerate IVD. The most clinically significant correlations however, are between IVD space narrowing due to DIVD and chronic LBP (CLBP), particularly when the former is associated with abnormal alignment and movement of the elements of the spinal motion segment. IVD space narrowing develops as DIVD progresses. Since it is now possible, using MR imaging, to recognise early stages of DIVD (i.e. before narrowing of the IVD space occurs) the combination of early diagnosis of DIVD and an effective treatment to halt/reverse its progression raises the prospect of significantly decreasing the incidence of CLBP. Furthermore novel forms of tissue engineering offer an approach to treating more advanced stages of DIVD.

The IVD provides reversible resistance to compressive, rotational and tensile loads applied to the vertebral column. These properties are a function of the structure of its major components – inner nucleus pulposus (NP), outer annulus fibrosus (AF) and superior and inferior cartilaginous end plates (CEP). These are, in general, hypocellular and avascular tissues, composed mainly of collagens and proteoglycans. The cells that populate these tissues maintain tissue composition and integrity. Unlike many tissues in which cells are in direct contact with one another, within the IVD, the cells are widely separated, and have an intimate two-way dynamic relationship with the matrix. *In vivo* IVD cells not only manufacture and



Maintain the matrix, but receive all nutrients by diffusion and bulk flow across it and through their interactions with it obtain key regulatory information, particularly that relating to the physical environment.

Many attempts have been made to develop therapies that will prevent the development of, and/or treat, spinal conditions characterized by degeneration of the intervertebral disc. Three avenues of research relate to:

- 1) The development of gene therapy techniques for delivering biologically active molecules to reverse the molecular processes leading to degeneration of the IVD.
- 2) The introduction of conditioned cells to produce normal IVD tissue to replace that lost in the process of IVD degeneration.
- 3) The production of tissue engineered IVD implants.

Each of these avenues requires the use of suitable cells. However, to date no useful source of cells exist and it is one object of the present invention to provide methods for the production and transformation of cells for use in 1-3 above.

According to a first aspect of the present invention there is provided an isolated mesenchymal stromal stem cell (MSSC) that has been differentiated *in vitro* towards, or to, an IVD cell phenotype for use as a medicament.

According to a second aspect of the present invention there is provided the use of an isolated mesenchymal stromal stem cell (MSSC) that has been differentiated *in vitro* towards, or to, an IVD cell phenotype in the manufacture of a medicament for the treatment of spinal conditions characterized by degeneration of the intervertebral disc.

According to a third aspect of the present invention there is provided a method of treating spinal conditions characterized by degeneration of the intervertebral disc comprising administering to a diseased intervertebral disc of a subject in need of such treatment an isolated mesenchymal stromal stem cell (MSSC) that has been differentiated *in vitro* towards, or to, an IVD cell phenotype.

By the term "IVD cells" we mean the cells that populate the inner nucleus pulposus (NP), outer annulus fibrosus (AF) and superior and inferior cartilaginous end plates (CEP) of the IVD. The cells within these three areas are also referred to herein as NP cells, AF cells or CEP cells respectively. Collectively these cells are referred to as IVD cells.

By the term "differentiated *in vitro* towards, or to, an IVD cell phenotype" we mean the MSSC cells have been treated such that the stem cell has matured down the lineage of NP cells, AF cells or CEP cells. Furthermore the morphology and particularly the functionality of the MSSC cells has changed to be more like NP cells, AF cells or CEP cells. It will be appreciated that it is preferred that the differentiation is complete as possible. However incomplete differentiation down the IVD lineage may still result in cells useful according to the present invention.

The present invention is based upon research relating to the IVD conducted by the inventors. They have realized that a key factor in the repair and regeneration of IVD tissue is to ensure that there are suitable cells in the IVD to mediate the repair/regeneration.

It has previously been proposed that suitable cells may be injected into the IVD and thereby regenerate the NP. One approach has been to harvest mature IVD cells from a patient's IVD and re-introduce them into an injured tissue. For instance, DE 42 19 626 contemplates the removal of somatic IVD cells from the spine and then reintroducing the cells (following genetic manipulation to improve their reparative qualities). However the inventors have found, to their surprise, when they explored the biology of these somatic cells in more detail, that this approach is flawed. This is because they have discovered that cells from a patient's damaged IVD have a senescent phenotype and thereby function poorly and rapidly die. Furthermore when such harvested cells are infected with a therapeutic gene, and injected into explant IVD, the inventors found that the cells only poorly express the introduced gene. The inventors also investigated cell replication potential (which falls with senescence) and expression of the cyclin-dependent kinase inhibitor P16<sup>INK4A</sup> protein (upregulated during cellular senescence), in tissue and cells of normal and degenerate NP. This showed age-related: decrease in replication potential; and increase in cellular expression of P16<sup>INK4A</sup>; in the normal NP. NP cells of degenerate IVD, however, even from young patients, exhibited a decrease in replicative potential and increased expression of P16<sup>INK4A</sup> equivalent to those of normal individuals who were as much as 40 years older. Furthermore, real time RT PCR demonstrated that there is a direct relationship between expression of senescent biomarkers

and the genes for: the matrix degrading enzymes MMPs 3 & 13; the aggrecanase, ADAMTs 5; and type I collagen; and an inverse relationship with expression of type II collagen and aggrecan.

The inventors realized that such data suggest that degenerate NP cells show a senescent phenotype with an altered cellular metabolism that may prevent their subsequent use in repairing the IVD. It was therefore realized that the use of cells as proposed by the prior art (e.g. DE 42 19 626) was unsuitable for the treatment of spinal conditions.

Having established that senescence was a problem in the use of cells for the treatment of spinal conditions, the inventors exerted inventive endeavor in attempt to identify other cell types that may be useful in the modulation of spinal conditions such a low back pain.

As described in more detail below, and in the Example, the inventors established that cells according to the first aspect of the invention may be used to treat spinal conditions. The use of cells according to the invention would not have been contemplated by the skilled person. In fact their use would be considered to be counter-intuitive. This is because the prior art suggests that cells taken directly from an IVD would be the best source of cells for use in therapy. Such a source of cells would immediately be selected because (a) the skilled person would have no knowledge of the senescence problems associated with IVD cells from diseased IVDs; and (b) the skilled person would be attracted to use differentiated IVD cells because they are already of the correct phenotype for possible manipulation and reintroduction into a diseased IVD.

It is possible that a skilled person may consider isolating IVD cells from a healthy IVD and transforming such cells prior to injection into a diseased IVD. The selection of such cells may have fewer problems with respect to senescence. However the choice of these cells would not be considered by a clinician because the extraction of such cells from a healthy IVD would result in an unacceptable risk that the patient may suffer as a consequence of the procedure and the healthy IVD would be damaged and thereby exacerbate the spinal condition.

Furthermore there would also be a technical prejudice against the selection of mesenchymal stromal stem cells for use in therapy of spinal conditions. Stem cells *per se* would not be useful and there are no known methods for the satisfactory differentiation of

MSSCs into IVD cells. Accordingly the skilled person, who would not benefit from the inventors knowledge relating to senescence or their skills in differentiation of MSSC, would automatically consider the use of cells that are already differentiated into IVD cells. The differentiation techniques used by the inventors represent further important aspects of the present invention and are discussed in more detail below.

Any form of mesenchymal stromal stem cell may be used according to the invention. Such cells may be harvested from blood, bone marrow, or adipose tissue (autologous MSSCs) according to techniques known to the art.

It is preferred that the MSSCs are taken from bone marrow (e.g. from the sternum, femur or iliac crest). A most preferred method of harvesting such cells is described in method 1.1.1 of Example 1.

The inventors have established that a number of differentiating techniques may be used (singularly or in combination) to cause mesenchymal stromal stem cells to differentiate towards IVD cells. Methods that may be employed according to the invention include:

**(A) IVD cell induction medium** - The inventors have established that standard cell culture media may be manipulated such that it includes active ingredients that promote differentiation of MSSCs into IVD cells.

NP cells share a common phenotypic lineage with articular chondrocytes and can advance along the common lineage pathway by growing them in a medium enriched with growth factors such as TGF $\beta$ . TGF $\beta$  usage does not always advance MSSC beyond the common precursor of the articular chondrocyte/NP cell. Therefore, if full differentiation is desired, it is preferred that this differentiation step is combined with other steps (see below).

By way of example, TGF- $\beta$ 3 may be added to cell culture media to promote differentiation. A preferred IVD cell induction medium comprises DMEM/HAMs F12 1:1 supplemented with glucose, L-ascorbic acid, suitable antibiotics, TGF- $\beta$ 3, dexamethosone, sodium pyruvate, proline and ITS +1 premix (ITS mix from Sigma with a premix comprising 1mg/ml insulin, 0.55mg/ml transferrin, 0.5 $\mu$ g/ml sodium selenite; 50mg/ml BSA and 470 $\mu$ g/ml linoleic acid). The cells may be cultured in the media for at least 1 day, preferably



at least 5 days and most preferably for about 12 days. A most preferred IVD cell induction medium is disclosed at 1.1.3.1 of Example 1.

**(B) Gel encapsulation** – Encapsulation of stem cells in alginate or other gels facilitates differentiation. Encapsulation in this or other gels may be used to promote differentiation and is particularly useful when used in conjunction with another technique (e.g. IVD cell induction medium). When this is the case the encapsulated cells may be exposed to the media for at least 1 day, preferably at least 5 days; more preferably for at least 12 days; and for periods up to 35 days. A preferred differentiation technique utilising encapsulation is described at 1.1.3.2 and 1.1.3.3 of Example 1.

**(C) Application of Load-** During their studies the inventors discovered that degenerate NP cells appear to be hypersensitive to loading at pressures as low as 1 psi (0.0069 Mpa [the minimum load on the normal intervertebral disc *in vivo* is 0.3 Mpa]). Experiments also showed that cellular responses were dependent on cell type and the frequency and amount of load applied. For instance significant differences were observed in gene expression from degenerate NP cells loaded at 5 psi (0.0345MPa) and at 7 psi (0.0483MPa).

Finding this lead them to realize that cells, useful in the treatment of back pain might be generated by applying particular loading conditions to cells during their preparation. They have subsequently shown that loading MSSC induces an NP phenotype. Load may be exerted on the cells in different ways including hydraulic loading of cells encapsulated in a gel supported by a plastic ring; by placing cells in culture or encapsulated in gels in a sealed chamber and applying pressure by influx of 5% CO<sub>2</sub> or through the application of balanced air at various pressures and delivery cycles, especially at pressures up to 7psi (0.048MPa) at varying frequencies (e.g. 3 seconds on and off or 5 seconds on and off) for different time periods (2 – 4 hours).

The application of load according to the regimens disclosed above and in the Examples represent a further important aspect of the invention. Therefore according to a sixth aspect of the invention there is provided a method for causing mesenchymal stromal stem cells to differentiate towards IVD cells comprising exposing cultured mesenchymal stromal stem cells to increasing pressures of up to 7psi (0.048MPa).

**(D) Co-culture of MSSCs with Nucleus Pulposus (NP) cells/IVD cells** –The inventors have established that normal NP cells and mesenchymal stromal stem cells (MSSCs) may be cultured together (with or without contact), with the result that the MSSCs differentiate towards IVD cells. Alternatively the MSSCs may be cultured in conditioned media (i.e. media in which NP cells have previously been grown).

The technique disclosed above and in the Examples (see 1.1.3.5) represent a further important aspect of the invention. Therefore according to a seventh aspect of the invention there is provided a method for causing mesenchymal stromal stem cells to differentiate towards IVD cells comprising co-culturing NP cells and mesenchymal stromal stem cells (MSSCs) together but without contact between the two cell types.

According to a eighth aspect of the invention there is provided a method for causing mesenchymal stromal stem cells to differentiate towards IVD cells comprising culturing mesenchymal stromal stem cells in media that has previously been exposed to NP cells.

**(E) Altering the gene expression profile of the cell using gene therapy** – This involves inserting a gene that regulates development of an NP phenotype (especially TGF $\beta$ , Sox-6, Sox-9) into an MSSC using a viral or non-viral vector that may either integrate or not integrate into the DNA of the MSSC. It is preferred that the exogenous gene is Sox – 9. It is preferred that a Sox-9 gene with the sequence contained within SEQ ID No 1 (see figure 11), or the gen sequec identified obn gene bank as accession number z46629, is used to infect the MSSCs. It is most preferred that the SOX-9 gene is inserted in a viral expression vector (see below) as illustrated in Figure 12. According to a further aspect of the invention there is provided a method for causing mesenchymal stromal stem cells to differentiate towards IVD cells comprising inserting into the MSSC a gene, and particularly the SOX- 9 gene, in an expression vector that regulates the development of an NP phenotype.

**(F) Oxygen tension-** The inventors have also found that altering the oxygen tension of cultured MSSC cells, and particularly making them hypoxic, may promote differentiation towards IVD cells.

For instance, MSSC may be cultured in a monolayer in media (e.g. by conventional techniques; as described in (A) above; or the Examples) in 0.1 – 20% O<sub>2</sub> for up to 4 weeks. Differentiation may be promoted at less than 10% O<sub>2</sub>; preferably at less than 5% O<sub>2</sub> and more

preferably at about 1% O<sub>2</sub>. Cells should be cultured at these oxygen tensions for at least a day, preferably at least 3 days and more preferably for about 1 week (or more). Data illustrating the usefulness of this differentiation procedure is given in Example 3.

The oxygen tension technique described above represents a further important aspect of the invention. Therefore according to an eighth aspect of the invention there is provided a method for causing mesenchymal stromal stem cells to differentiate towards IVD cells comprising culturing mesenchymal stromal stem cells (MSSCs) in an atmosphere comprise 5% or less Oxygen.

It will be appreciated that differentiation steps (A) – (F) may be used singularly or in combination to induce MSSCs to differentiate into cells with an IVD cell phenotype.

According to a preferred differentiation procedure, the MSSCs are conditioned to adopt an NP phenotype by placing them in a simple gel (such as alginate) and loading them whilst being cultured in a medium containing TGF $\beta$ . The encapsulated cells may be grown in a medium containing TGF $\beta$ , for between 2 days and 6 weeks during which a load is exerted using a cyclical compressive load of 2 to 100 psi at between 0.1 and 2 (typically 0.5) Hz.

According to another preferred differentiation procedure, MSSC may be encapsulated in alginate (e.g. as described above) and exposed to a dynamic cyclical compressive load ( 0-4mPa) at a rate of between 0.5 and 3 Hz for between 1 and 35 days. More preferably the load may be applied as 0.8-1.7mPa at 1 Hz for 4hours repeated every 48hours for 7 days. Data illustrating the usefulness of this differentiation procedure is given in Example 4.

Cells differentiated according to the first aspect of the invention may be used for a number of therapeutic uses. For instance, the cells may be administered to a diseased intervertebral disc of a subject in need of such treatment or by seeding onto or into a biomaterial *in vitro* to be implanted or injected into the patient's intervertebral disc. The biomaterial may be a natural compound or material (e.g. collagen) or may be a synthetic material.

According to a preferred embodiment of the invention undifferentiated pluripotent mesenchymal stromal stem cells (MSSCs according to the invention) may be differentiated toward IVD cells. Such cells may be used to repopulate the IVD with viable cells or may also



be used to seed biomaterial scaffolds and gels for the management of DIVD according to the invention. These three therapeutic uses may be combined as the clinical need dictates.

Briefly autologous undifferentiated pluripotent mesenchymal stromal cells may be harvested from the patient's own marrow, peripheral blood and/or adipose tissue and then grown to confluence *in vitro*. The MSSCs are then transferred to a medium in which they will be differentiated into nucleus pulposus (NP) cells according to the preferred procedures described above. After this the now differentiated and conditioned MSSC-derived IVD cells will be used to:

- (a) Repopulate the IVD by direct injection into the diseased IVD with the purpose of their producing fresh matrix; or
- (b) Seed biomaterial scaffolds and gels *in vitro* to produce tissue engineered implants suitable for restoring IVD matrix and/or function.

The inventors have also realised that the IVD is avascular. This limits access of oral or systemically delivered pharmaceutical agents to native IVD cells. Furthermore repeated injection of such agents directly into the IVD is also problematic because of the proximity to important organs (eg. aorta, spinal cord) and the risk of introducing infection. Accordingly the inventors have recognized that there is need for providing improved means for delivering therapeutic agents to the IVD. This lead to a further aspect of the invention, described in more detail below, whereby cells according to the first aspect of the invention may be adapted for the delivery of therapeutically active agents.

The inventors work has shown that biological agents (eg. IL-1Ra, TGF, TIMPs) could be used therapeutically raising the possibility of a gene therapy approach to managing DIVD. Within the current climate the use of *in vivo* gene therapy for treating spinal conditions raises a number of problems. Using the *in vivo* approach would entail injecting an expression vector (usually a viral vector) into the IVD at an unknown concentration (in terms of vectors per cell). The addition of viral vectors at high MOIs has cytotoxic effects, and as cell number in the degenerate IVD is unknown and cannot be determined easily, the addition of toxic concentrations of viral vector would be a clear possibility. In addition the mis-injection of viral vector into: (a) a blood vessel may result in a systemic immune response, which could be fatal; and (b) a recent study by Wallach *et al.*, (2003: 84 International Society for the Study of

(The Lumbar Spine, Conference Abstract), demonstrated the strong possibility of inducing paralysis following mis-injection of a TGF  $\beta$  adenoviral vector at high dose into areas surrounding the IVD (Wallach *et al.* 2003 *supra*)

The use of an *ex vivo* gene therapy approach (i.e. *in vitro* transformation of cells with a therapeutic gene and then introducing the cells into a subject) has been contemplated for the treatment of degenerative back conditions. This approach has a number of advantages over the use of *in vivo* gene transfer. One of the clearest advantages of such an approach would be the ability to perform extensive safety controls before the insertion of cells into the IVD. In addition higher levels of transgene could potentially be produced, as cells could be selected prior to injection into the IVD for production of high levels of therapeutic protein. One attempt at an *ex vivo* gene therapy approach to the treatment of spinal conditions is disclosed in DE4219626.

However to date none of these *in vivo* or *ex vivo* gene therapy approaches have been successful enough to be used in the clinic. The inventors have found that IVD cells produced from MSSC may be more successful in this capacity and according to a ninth aspect of the present invention there is provided an isolated mesenchymal stromal stem cell (MSSC) that has been:

- (a) differentiated *in vitro* towards an IVD cell phenotype; and
- (b) transfected with an exogenous gene which codes for a protein that reduces degeneration of an intervertebral disc.

MSSC/IVD cells according to the first aspect of the invention may be genetically transformed with the exogenous gene before or after the process of full differentiation has been completed.

The exogenous gene must be cable of being expressed from the cells (preferably *in vitro* as well as when administered to a subject) to produce a protein that directly or indirectly has activity for reducing degeneration of an intervertebral disc. By “directly” we mean that the product of gene expression *per se* has the required activity. By “indirectly” we mean that the product of gene expression undergoes or mediates (e.g. as an enzyme) at least one further reaction to provide an agent effective for reducing degeneration of an intervertebral disc.

The exogenous gene may be selected from a number of genes that have known activity for reducing inflammation. These include: cytokines (especially molecules of the TGF $\beta$  superfamily); inhibitors of cytokines (especially the specific interleukin-1 inhibitors, interleukin-1 receptor antagonist [IL-1ra] and the soluble type II interleukin-1 receptor [IL-1RII]) and inhibitors of degradative enzymes, (especially TIMPs 1, 2 and 3 and other inhibitors of matrix metalloproteinases and ADAMTs)

A preferred exogenous gene codes for the Interleukin 1 Receptor Antagonist (IL-1RA). IL-1RA is a natural inhibitor of IL-1. The inventors have shown that IL-1RA is produced by normal intervertebral disc cells together with IL-1 but in an excess over the cytokine that would inhibit IL-1 activity. However they have demonstrated in diseased IVD that IL-1 but not IL-1RA production is up-regulated. The implication of this finding is that there is a relative shortfall in IL-1RA production in spinal conditions according to the invention. Therefore the exogenous gene preferably codes IL-1RA.

The exogenous gene may be contained within a suitable vector to form a recombinant vector. The vector may for example be a plasmid, cosmid or phage. Such recombinant vectors are highly useful for transforming cells with the exogenous gene.

Recombinant vectors may also include other functional elements. For instance, recombinant vectors may be designed such that the vector will autonomously replicate in the nucleus of the cell. In this case, elements that induce DNA replication may be required in the recombinant vector. Alternatively the recombinant vector may be designed such that the vector and recombinant DNA molecule integrates into the genome of a cell. In this case DNA sequences that favour targeted integration (e.g. by homologous recombination) are desirable. Recombinant vectors may also have DNA coding for genes that may be used as selectable markers in the cloning process.

The recombinant vector may also further comprise a promoter or regulator to control expression of the gene as required.

The exogenous gene may be inserted into a retroviral vector. Such vectors may advantageously fully integrate into the host genome. This results in long-term gene expression, with integrated genes passed onto daughter cells.

Recently however a gene therapy patient, undergoing treatment for severe combined immune deficiency (SCID) using a retroviral vector, was cured of SCID but developed a leukaemia-like condition thought to be caused by 'insertional mutagenesis' of the retrovirus. In addition retroviruses have also been shown to cause leukaemia within mice. This suggests that it may be detrimental to use retroviral vectors. It is therefore preferred that the exogenous gene is inserted in an adenoviral vector. The use of adenoviral vectors avoids the risk of insertional mutagenesis as the vector remains episodic and is not integrated into the genome. In addition the Ad vector has good transduction ability to quiescent, non-dividing, highly differentiated cells.

The inventors believe that adenoviral vectors are useful in an *ex vivo* approach to gene transfer in the IVD. In most cases of gene transfer the inability to integrate into the genome by adenoviruses is considered to result in the short life of the transgene, as it is lost during cellular division. However, within the IVD where cellular turnover rates are very low this will not cause the same problems, and long term gene expression is possible..

According to a tenth aspect of the invention there is provided a recombinant vector suitable for genetically transforming mesenchymal stromal stem cells, or IVD cells produced from them according to the ninth aspect of the invention, comprising an adenoviral expression vector containing a gene encoding a protein that reduces DIVD.

Preferred recombinant vectors according to the tenth aspect of the invention are described in Example 2.

It will be appreciated that the exogenous gene may be delivered to the MSSC without it being incorporated in a vector. For instance, the exogenous gene may be incorporated within a liposome or virus particle. Alternatively the "naked" DNA molecule may be inserted into the MSSCs by a suitable means e.g. direct endocytotic uptake.

The exogenous gene (contained within a vector or otherwise) may be transferred to the MSSCs (before or after differentiation towards IVD cells) by transfection, infection, microinjection, cell fusion, protoplast fusion or ballistic bombardment. For example, transfer may be by ballistic transfection with coated gold particles, liposomes containing the exogenous gene, and means of providing direct DNA uptake (e.g. endocytosis).



It is preferred that the cells are infected with the exogenous gene during the differentiation process.

When the cells are encapsulated in gel it is preferred that infection occurs during gel encapsulation. Cells to be infected in gel are preferably infected via the addition of viral suspension to gel cell suspension before polymerisation. A most preferred infection protocol is given in Example 1.

It will be appreciated that cells according to the ninth aspect of the invention may be used for the same purposes as those described above for those according to the first aspect of the invention. Furthermore the cells according to the ninth aspect of the invention have the advantage that they have been engineered to contain a therapeutically effective agent that may have efficacy against DIVD.

The invention will be illustrated further by Example and with reference to the following drawings, in which:

**Figure 1** illustrates the Level of gene expression for Sox 9 and aggrecan in MSSCs cultured in IVD cell inducing media as described in Example 1;

**Figure 2** illustrates proteoglycan production in gel constructs loaded at 5 psi 3 sec on 3 sec off for 2.5 hours as described in Example 1;

**Figure 3** illustrates results from Real-time PCR showing changes in SOX-9 mRNA expression (A) and aggrecan mRNA expression (B) in monolayer MSSC and NP cells over time (samples normalised to GAPDH and cells in single population culture) as described in Example 1;

**Figure 4:** Immunohistochemical staining for aggrecan (A), collagen type II (B), or collagen type I (C) within alginate bead cultures infected with Ad-LacZ (ii) and uninfected cells (i) (Bars = 380nm) as described in Example 2;

**Figure 5:** Gene expression of the matrix proteins aggrecan, collagen type II and collagen type I following infection of cells with Ad-GFP within alginate beads 5 weeks post infection as described in Example 2;

**Figure 6:** IL-1 Ra protein production 2 days post infection within cells infected with IL-1Ra MOI 300 cultured in. Error bars = standard error of the mean. Statistical analysis  $p < 0.1$  for Normal AF cells,  $p < 0.05$  = all other cells, \* = Probability values for difference between uninfected and infected cells. ■ = Probability values for difference between NP and



AF cells. ▲ = Probability values for difference between normal and degenerate cells as described in Example 2;

**Figure 7:** Gene expression of IL-1 Ra following infection within alginate culture and culture within alginate beads for 5 weeks; Error bars = Standard error of the mean; and statistical significance as described in Example 2;

**Figure 8:** IL-1Ra production in degenerate NP (A) and AF (B) cells infected in alginate culture for 72 days as described in Example 2;

**Figure 9:** Gene expression of MMP 3 (A) and MMP 13 (B) in IVD cells (uninfected and infected with Ad-IL-1Ra (MOI 300)) treated with IL-1 $\beta$  and cultured in monolayer; Error bars = standard error of the mean; Statistical analysis  $p < 0.1$  = \* or ▲,  $p < 0.05$  = \*\* or ▲▲; Asterisks = probability values for difference between untreated and treated cells; Triangles = probability values for difference between uninfected and infected cells as described in Example 2;

**Figure 10:** Real-time PCR data showing relative gene expression of matrix component molecules after SOX-9 transfection (A) and SOX-9 transfection with TGF- $\beta$ 1 stimulation (B) of monolayer MSSCs. Samples are normalised to GAPDH and GFP-transfected, unstimulated controls as described in Example 2;

**Figure 11:** represents a sequence of a vector comprising Sox 9 gene as described in Example 2;

**Figure 12:** represents a vector map of a preferred expression vector containing Sox 9

**Figure 13:** is a bar chart illustrating gene expression of Sox-9, aggrecan and Collagen type II in MSSC cells cultured in monolayer in 1% and 20% oxygen for 2 weeks according to Example 3; and

**Figure 14** is a bar chart illustrating proteoglycan production (a marker of differentiation towards NP cells) using a preferred differentiation technique described in Example 4.

## **EXAMPLE 1: Mesenchymal stromal stem cell harvesting, Cell culture and IVD Cell**

### **Differentiation**

#### **1.1 METHODS**

##### **1.1.1 Mesenchymal stromal stem cell harvesting**

Mesenchymal stromal stem cells were harvested from iliac crest bone marrow aspirates. 5-10ml of marrow are placed into 4.45 ml HBSS, 0.05 ml of PSA and 0.5ml of heparin (100 units) at the time of harvest. The sample is centrifuged at 500g for 10 minutes. The supernatant is removed and the pellet resuspended in 5ml of  $\alpha$ MEM. The cell suspension is then transferred to a 15 ml centrifuge tube and 5ml of histopaque 1077 added to the tube below the medium. The tube is centrifuged at 500g for 30 minutes to isolate the stromal cells. Following centrifugation the grey interface layer containing the mononuclear cells is removed by gentle aspiration, passed through a cell strainer and resuspended in standard media ( $\alpha$ MEM, 10% FCS, 1% glutamine, 1% ascorbate and 1% penicillin, streptomycin and amphotericin in T75 culture flask. Cells are incubated at standard culture conditions (37°C in 5% CO<sub>2</sub>). Cells are left to settle for 1 week without any change of media, and then the media is removed, cells washed in PBS and fresh media added. Media thereafter is changed every 2-3 days, and cells expanded through 2-3 passages by standard methods.

##### **1.1.2 Cell culture of IVD cells**

The IVD cells are cultured in DMEM + F12 media supplemented with 10% heat inactivated fetal calf serum (FCS) (Gibco), 100U/ml Penicillin (Sigma), 100 $\mu$ g/ml Streptomycin (Sigma), 250ng/ml amphotericin, 2mM glutamine (Sigma) and 50 $\mu$ g/ml ascorbic acid (Sigma) in T75 flasks (Appleton woods) and cultures maintained at 37°C in a humidified atmosphere containing 5% CO<sub>2</sub>. Culture media is changed every other day.

##### **1.1.3 Production of IVD cells from Mesenchymal stem cells**

A number of differentiating techniques were used singularly or in combination:

**1.1.3.1 IVD cell induction medium** - DMEM/HAMs F12 1:1 supplemented with 1.349g glucose, 50 $\mu$ g/ml L-ascorbic acid, 100units/ml penicillin, 100  $\mu$ g/ml ml streptomycin, 250  $\mu$ g/ml 250ng amphotericin, 10ng/ml TGF- $\beta$ 3, 1 x10<sup>-7</sup> M dexamethosone, 100  $\mu$ g/ml sodium pyruvate, 40  $\mu$ g/ml proline and 1% ITS + 1 premix. (ITS mix from Sigma with a premix





(comprising 1mg/ml insulin, 0.55mg/ml transferin, 0.5µg/ml sodium selenite; 50mg/ml BSA and 470µg/ml linoleic acid)

**1.1.3.2 Alginate encapsulation** - Monolayer stromal cells are trypsinized and the resulting cell suspension centrifuged at 500g. The cell pellet is then resuspended in 10 ml of stromal media, and cells counted using a coulter counter. Following another centrifugation at 500g the cells are then resuspended in 1.2% medium viscosity alginate in 0.15M NaCl at a density of  $1 \times 10^6$  cell/ml. The resulting suspension is then expressed through a 22 gauge needle using a 5ml syringe in to 12 well plates containing 102nM  $\text{CaCl}_2$  to form polymerized microspheric beads. After 10 minutes the polymerized alginate is washed in normal saline, followed by a wash in standard medium.

**1.1.3.3 Induction of IVD cell phenotype**- Cells encapsulated in alginate are then placed in the IVD cell induction media and cultured under standard conditions for up to 12 days.

**1.1.3.4 Application of Load**- Cells are loaded within 24 well plates in alginate constructs. The plate is placed into a sealed chamber and pressure applied by influx of 5%  $\text{CO}_2$ , balanced air at pressures up to 7psi (0.048MPa) at varying frequencies ( 3 seconds on and off, and 5 seconds on and off) for different time periods ( 2 – 4 hours).

**1.1.3.5 Co culture of MSSCs with Nucleus Pulposus (NP) cells** -Normal NP cells (P3) and MSSCs (P3) are grown in monolayer to confluence and then trypsinised and counted. Cells are then cultured together but without contact, in the ratio of 60,000 NP cells and 30,000 MSSCs. For the without contact wells, NP cells are pipetted into the bottom of the wells and then a tissue culture insert is placed in the well and MSSCs pipetted onto the insert. 2mls DMEM-F12 + FCS are then added to each well and cells Incubated under standard conditions.

## **1.2 RESULTS**

The Inventors conducted experiments that confirmed that cells used in the art were unsuitable for the treatment of degenerative IVDs.

Key to the strategy of repair and tissue engineering of the IVD is the generation of suitable cells for injecting into and regenerating the NP. One approach has been to harvest cells from the patient's IVD. Although many workers use these cells, the inventors surprisingly found that this approach is flawed because the cells have a senescent phenotype, cannot withstand

the loads of the IVD, and when infected with IL-1Ra adenovirus and injected into explant IVD cannot increase IL-1Ra in the tissue.

### ***1.2.1 Evidence of Cellular Senescence***

The inventors investigated cell replication potential (which falls with senescence) and expression of the cyclin-dependent kinase inhibitor P16<sup>INK4A</sup> protein (upregulated during cellular senescence), in tissue and cells of normal and degenerate NP. This showed age-related: decrease in replication potential; and increase in cellular expression of P16<sup>INK4A</sup>; in the normal NP. NP cells of degenerate IVD, however, even from young patients, exhibited a decrease in replicative potential and increased expression of P16<sup>INK4A</sup> equivalent to those of normal individuals as much as 40 years older. In addition they have shown by real time RT PCR that there is a direct relationship between expression of senescent biomarkers and the genes for: the matrix degrading enzymes MMPs 3 & 13; the aggrecanase, ADAMTs 5; and type I collagen; and an inverse relationship with expression of type II collagen and aggrecan. Such data suggest that degenerate NP cells show a senescent phenotype with an altered cellular metabolism that may prevent their subsequent use in repairing the IVD.

### ***1.2.2 Effect of Load***

Preliminary data shows that degenerate NP cells appear to be hypersensitive to loading at pressures as low as 1 psi (0.0069 Mpa – the minimum load on the intervertebral disc is 0.3 Mpa ). Our experiments also show that cellular responses are dependent on cell type and the frequency and amount of load applied. For instance significant differences were observed in gene expression of degenerate NP cells loaded at 5 psi (0.0345MPa) and at 7 psi (0.0483MPa)

### ***1.2.3 IL-1Ra adenoviral infected IVD cells***

The ability of cells infected with Ad-IL-1Ra to contribute to increased total production of IL-1Ra in the tissue was also studied. Cells derived from degenerate and non-degenerate IVD were infected with Ad-IL-1Ra, labeled with CFDA-SE and injected into explants of degenerate human IVD. CFDA-SE labelled cells were identified in all tissue explants. When normal IVD cells infected with Ad-IL-1Ra were injected into the tissue explants a significant increase in IL-1Ra immuno-positive cells was observed. However, when Ad-IL-1Ra infected degenerate cells were injected into the tissue explants no increase in the proportion of IL-1Ra immunopositive cells was observed. This demonstrates that the use of degenerate IVD cells may be inappropriate for the transfer of IL-1Ra to the degenerate IVD.

### ***1.2.4 Production of IVD cells from MSSC***



Mesenchymal cells cultured in alginate and treated with IVD cell inducing media show increased gene expression of Sox 9 and aggrecan after 11 days (Figure 1)

#### ***1.2.5 Effect of Load in Inducing an IVD cell phenotype***

Culture of MSSC cells in alginate cultures under compressive load resulted in equivalent proteoglycan production to NP cells cultured under the same conditions, with an increase in proteoglycan content with time in culture. (Figure 2)

#### ***1.2.6 Co-Culture of MSSC with NP cells***

Co-culturing MSSC with normal NP cells led to differentiation of the MSSC into NP cells. In addition real-time PCR showed that both the NP cells and MSSCs increased expression of SOX-9 gene (figure 3). Cells were maintained without contact, suggesting factors released by NP cells will cause MSSC to differentiate into NP cells.

## XAMPE 2: Gene Transfer

This example illustrates the work conducted by the inventors to insert an exogenous gene (IL-1RA) into dedifferentiated NP cells. NP cells when passaged 2 -3 times in culture tend to spontaneously dedifferentiate in culture towards a MSSC phenotype. Accordingly, such dedifferentiated cells represent a good model of MSSCs according to the invention.

2.1 Choice of Viral vectors - The retroviral vector's capability to fully integrate into the host genome results in long term gene expression, with integrated genes passed onto daughter cells. However mutagenesis is a possibility if viral insertion was to occur in a non-favourable site. Recently within a gene therapy patient in France, who was undergoing treatment for severe combined immune deficiency (SCID) using a retroviral vector, was cured of SCID but developed a leukaemia like condition thought to be caused by 'insertional mutagenesis' of the retrovirus. In addition retroviruses have also been shown to cause leukaemia within mice. These studies appear to be detrimental to the use of retroviral gene transfer. The use of adenoviral vectors avoids the risk of insertional mutagenesis as the vector remains episodic and is not integrated into the genome. In addition the Ad vector has good transduction ability to quiescent, non-dividing, highly differentiated cells. Adenoviral vectors may be useful in an *ex vivo* approach to gene transfer in the IVD. In most cases of gene transfer the inability to integrate into the genome by adenoviruses is considered to result in the short life of the transgene, as it is lost during cellular division. However, within the IVD where cellular turnover rates are low this may not cause the same problems, and long term gene expression may be possible. In addition, loss of adenoviral gene transfer is often caused by immune reactions to viral proteins, or to the foreign proteins encoded by the transgenes. However this may not cause a problem within the IVD, as the IVD is considered an immuno-privileged site.

*Viral Vector*- Ad-IL-1Ra vector was a kind gift from Professor Christopher H Evans (Harvard University, Boston). Briefly IL-1Ra cDNA was cloned from a human monocyte cDNA library as detailed by Bandara *et al.*, (1993 Proc, Natl. Acad. Sci USA 90: 10764-10768). First generation, E1, E3-deleted serotype 5 recombinant adenoviral vector containing IL-1Ra was then constructed using *Cre-lox* recombination by the system of Hardy *et al.*, (1997 J Virol 71, 1842-1849). All three adenovirus constructs were grown within 293 cells, and following lysis, the viral suspension was purified using CsCl density gradient purification (Bet, Prevec *et al.* J Virol 67, 911-5921).





**2.2 Infection Protocol** - Preferred timing of infection is during alginate encapsulation. Cells to be infected in alginate are infected via the addition of viral suspension (correct volume calculated as for monolayer) to alginate cell suspension before polymerisation. In brief following expansion in monolayer culture cells are trypsinized and cell suspensions spun at 300g for 5 minutes to generate a cell pellet. The cell pellet is then resuspended in 10ml of DMEM + F12 and cell number counted using a coulter counter ZM (Coulter electronics). Following further pelleting, cells are resuspended in 1.2 % low viscosity sodium alginate in 0.15M NaCl at a density of  $1 \times 10^6$  cells/ml and appropriate amount of viral suspension added. Following mixing the cell/viral suspension is passed through a 23 gauge needle into a 12 well plate containing 200mM  $\text{CaCl}_2$  where each drop was instantly polymerised forming semisolid microspheric beads. Beads are incubated for 10 minutes at  $37^\circ\text{C}$  to allow further polymerisation, followed by two washes in 0.15M NaCl and two washes in serum free media. Two millilitres of IVD cell induction media is added to each well and cultures maintained at  $37^\circ\text{C}$  in a humidified atmosphere containing 5%  $\text{CO}_2$ .

### **2.3 Effect of IL-1 RA gene transfer on cells**

***2.3.1 Phenotypic stability of virally infected cells*** No difference was seen between Ad-LacZ infected cells and non-infected cells in the staining pattern of any of the matrix proteins investigated (aggrecan ( $p=0.499$ ), collagen II ( $p=0.5$ ) and collagen type I ( $p=0.498$ )). With high proportions of cells positive for type II collagen and aggrecan and low proportions of positive cells for collagen type I even after 4 weeks in culture (Figure 4). Similar results were seen in cells infected with Ad-GFP with no significant difference within any cell type in any of the matrix proteins investigated, compared to non-infected cells (Figure 5) (probability values for total cells: Aggrecan  $p=0.786$ , Collagen type II  $p=0.954$ , Collagen type I  $p=0.3588$ ).

### ***2.3.2 IL-1Ra production following gene transfer***

Infection of cells in alginate resulted in a significant increase in IL-1Ra protein 48 hours post infection in all cell types investigated (normal NP  $p<0.05$ , degenerate NP  $p<0.05$ , normal AF  $p<0.1$  and degenerate AF  $p<0.05$ ) compared to IL-1Ra production in uninfected cells (Figure 6).

Uninfected degenerate NP cells showed significantly higher levels of IL-1Ra than uninfected degenerate AF cells ( $p<0.05$ ). In addition Ad-IL-1Ra infected degenerate NP cells

also showed higher IL-1Ra protein than Ad-IL-1Ra infected degenerate AF cells ( $p < 0.05$ ) (Figure 6). Normal IVD cells did not show any significant difference in IL-1Ra production between NP and AF cells. Uninfected normal cells did not show any significant difference in IL-1Ra production to uninfected degenerate IVD cells. However, Ad-IL-1Ra infected normal cells showed higher IL-1Ra production than infected degenerate cells (NP cells ( $p < 0.05$ ), AF cells ( $p > 0.1$ )) (Figure 6). Following culture for a further 5 weeks in alginate cells infected with Ad-IL-1Ra showed elevated IL-1Ra gene expression in all cell types (normal NP  $p < 0.05$ , degenerate NP  $p < 0.1$ , normal AF  $p < 0.05$ , degenerate AF  $p < 0.05$ ) compared to uninfected cells (Figure 7).

#### ***2.3.4 Length of transgene expression in alginate culture***

Degenerate NP cells infected with Ad-IL-1Ra (MOIs 300 and 1500) in alginate produced significantly higher levels of IL-1Ra protein than uninfected control cells 2 days post infection (MOI 300  $p < 0.05$ , MOI 1500  $p < 0.05$ ) and at all subsequent time points (all  $p$  values  $< 0.05$ ). Levels were significantly higher in cells infected at an MOI of 1500 than those infected at an MOI of 300 ( $p < 0.05$ ) (Figure 8A). Cells infected with Ad-GFP did not show any significant difference in IL-1Ra protein production over the time course investigated (all  $p$  values  $> 0.1$ ) (Figure 8A).

Degenerate AF cells infected with Ad-IL-1Ra (MOI 300 and 1500) in alginate also showed significantly higher levels of IL-1Ra protein compared to uninfected control cells 2 days post infection (MOI 300  $p < 0.05$ , MOI 1500  $p < 0.05$ ). In addition significantly higher levels of IL-1Ra protein were seen in cells infected with Ad-IL-1Ra at an MOI of 1500 than those infected with an MOI of 300 ( $p < 0.05$ ) (Figure 8B). No difference in levels of IL-1Ra protein were seen in Ad-GFP infected cells compared to uninfected controls (all  $p$  values  $> 0.1$ ). At all time points studied, degenerate AF cells infected with Ad-IL-1Ra (MOI 300 & 1500) showed no significant decrease in levels of IL-1Ra from those produced following 2 days post infection (all  $p$  values  $> 0.1$ ). Normal NP and AF cells infected with Ad-IL-1Ra (MOI 300) showed significantly higher levels of IL-1Ra protein than uninfected control cells ( $p < 0.05$ ) 2 days post infection. After 5 weeks in alginate culture no significant change in levels of protein were seen. Levels of IL-1Ra protein in infected cells remained significantly higher than control cells even following 5 weeks in alginate culture ( $p < 0.05$ ).

### ***2.3.5 Inhibition of IL-1 with IL-1Ra***

Treatment of IVD cells in monolayer culture for 48 hours with IL-1 $\beta$  resulted in a significant increase in the gene expression of MMP 3 and MMP 13 (Figure 9). In all cell types the response to IL-1 $\beta$  was inhibited by infection of cells with Ad-IL-1Ra (MOI 300) with decreased MMP 3 and MMP 13 gene expression (Figure 9).

### **2.4 Transfection of dedifferentiated NP cells with Sox-9 adenovirus**

Transfection of monolayers of dedifferentiated NP cells with adenoviral SOX-9 led to their developing an NP phenotype in monolayer that was improved by addition of TGF- $\beta$ 1 (Figure 10). The results show TGF- $\beta$ -stimulated, SOX-9 transfected, monolayer MSSCs, produce a large population of dividing cells that have an NP-like phenotype that are readily accessible for use in tissue engineering applications

The sequence of the Sox-9 vector used in this Example is given in Figure 11 and a restriction map shown in Figure 12. The Sox-9 gene sequence comprised bases 1265-27222 (gene bank accession number z46629)

### **EXAMPLE 3**

Experiments were conducted to illustrate the effectiveness of reducing oxygen tension as a means of differentiating MSSC cells towards NP cells.

MSSC cells were isolated and cultured as described in Example 1 at 1.1.1 and 1.1.2. These cells were then transformed with Sox-9 as described in Example 2 in order that expression of Sox 9 may be monitored as a marker of differentiation. Expression of aggrecan and Collagen type II was also monitored as a marker of differentiation.

Figure 13 illustrates that MSSC cells cultured in monolayer in 1% oxygen for 2 weeks differentiated towards NP cells whereas cells cultured in monolayer in 20% oxygen for 2 weeks expressed negligible amounts of differentiation markers.



#### **EXAMPLE 4**

The inventors conducted further development work whereby the differentiation steps described above (and particularly in Example 1 and 3) were combined.

The inventors found that using more than one differentiation technique could improve differentiation. For instance, MSSC cells encapsulated in alginate and loaded 3 times a week for 4 hours under a light exercise loading regime (0.8-1.7MPa, 1Hz) resulted in a doubling of total proteoglycan content of the alginate construct over 1 and 3 weeks in culture. Such cells had phenotypes closely resembling natural NP cells. Figure 14 illustrates proteoglycan production ( a differentiation markers) from such cells.

## CLAIMS

1. An isolated mesenchymal stromal stem cell (MSSC) that has been differentiated *in vitro* towards, or to, an IVD cell phenotype for use as a medicament.
2. An isolated mesenchymal stromal stem cell (MSSC) characterised in that it is:
  - a) differentiated *in vitro* towards, or to, a IVD cell phenotype; and
  - b) genetically transformed with an exogenous gene which codes for a protein that reduces degeneration of an intervertebral disc.
3. The isolated mesenchymal stromal stem cell according to claim 1 or 2 that is derived from blood, bone marrow, or adipose tissue.
4. The isolated mesenchymal stromal stem cell according to claim 3 that is derived from bone marrow in the sternum, femur or iliac crest.
5. The isolated mesenchymal stromal stem cell according to any preceding claim wherein the MSSCs are differentiated using any one of the steps:
  - (a) growth in a IVD cell induction medium containing TGF $\beta$ ;
  - (b) encapsulation of the MSSC;
  - (c) application of Load to the MSSCs;
  - (d) Co-culture of MSSCs with Nucleus Pulposus cells/IVD cells;
  - (e) Culture of the MSSCs in conditioned media in which IVD cells have previously been grown;
  - (f) Culture in low oxygen tensions; or
  - (g) Genetically transformed using a gene regulatory of IVD cell differentiation
6. The isolated mesenchymal stromal stem cell according to claim 5 wherein differentiation is effected by using steps any combination of (a), (b), (c), (d), (e) (f) and (g) of claim 5.
7. The isolated mesenchymal stromal stem cell according to claim 6 wherein the MSSCs are differentiated by encapsulating MSSCs in a gel; and growing the encapsulated cells in a

medium for up to 5 weeks during which time a cyclical load equivalent to that experienced in vivo is exerted using hydraulic or other methodology

8. The isolated mesenchymal stromal stem cell according to claim 7 wherein the media also contains TGF $\beta$  and/or the oxygen pressure is reduced to less than 5% of the atmosphere in which the cells are cultured.
9. A method for causing mesenchymal stromal stem cells to differentiate towards IVD cells comprising exposing cultured mesenchymal stromal stem cells to increasing pressures of up to 30 psi (2.1MPa).
10. A method for causing mesenchymal stromal stem cells to differentiate towards IVD cells comprising co-culturing NP cells and mesenchymal stromal stem cells (MSSCs) together.
11. A method for causing mesenchymal stromal stem cells to differentiate towards IVD cells comprising culturing mesenchymal stromal stem cells in media that has previously been exposed to NP cells.
12. A method for causing mesenchymal stromal stem cells to differentiate towards IVD cells comprising culturing mesenchymal stromal stem cells in an atmosphere in which oxygen pressure is reduced to less than 5%.
13. The isolated mesenchymal stromal stem cell according to any one of claims 2- 8 wherein the exogenous gene may be selected from the group of genes encoding proteins involved in the regulation of inflammation and the group comprises genes encoding cytokines; inhibitors of cytokines; and inhibitors of degradative enzymes
14. The isolated mesenchymal stromal stem cell according to any one of claims 2- 8 wherein exogenous gene encodes Interleukin 1 Receptor Antagonist (IL-1RA).
15. A use of a cell according to any one of claims 1 -8, 13 or 14 in the manufacture of a medicament for the treatment of spinal conditions characterized by degeneration of the intervertebral disc.
16. The use according to claim 15 wherein the spinal condition is Low Back Pain, degeneration of the intervertebral disc, age-related changes of the intervertebral disc or spondylolysis.



17. The use of a cell according to claims 15 or 16 wherein the cells are for direct injection into an IVD exhibiting DVID.


18. The use of a cell according to claims 15 or 16 wherein the cells are for seeding onto or into biomaterial scaffolds or gels .

19. A method of treating spinal conditions characterized by degeneration of the intervertebral disc comprising administering to a diseased intervertebral disc of a subject in need of such treatment an isolated MSSC that has been differentiated *in vitro* towards, or to, an IVD cell phenotype.


20. A method of treating spinal conditions characterized by degeneration of the intervertebral disc comprising administering to a diseased intervertebral disc of a subject in need of such treatment an isolated MSSC, wherein said MSSC has been has been:

- (a) differentiated *in vitro* towards, or to, a IVD cell phenotype; and
- (b) genetically transformed with an exogenous gene which codes for a protein that reduces degeneration of an intervertebral disc.

**FIG. 1**




**FIG. 2**






**FIG. 3**




**FIG. 4**









**FIG. 5**




**FIG. 6**






**FIG. 7**




**FIG. 8**







**FIG. 9**







**FIG. 10**





**Fig. 11**

catcatcaataataccttattttggattgaagccaatatgataatgagggggtggagtttgacgtggcgcgggggtgg  
gaacggggcggtgacgtagtagtggtggcggaagtgtgatgttgcaagtgtggcggaacacatgtaagcgacggatgtg  
gcaaaagtacgttttgggtgtgcgccggtgtacacaggaagtgacaatttcgcgcggttttaggcggatgtttagtaaatt  
tgggcgtaaccgagtaagatttggccattttcgcgggaaaactgaataagaggaagtgaatctgaataattttgtgtactca  
tagcgcgtaataatttgtctagggccgcggggactttgaccgtttacgtggagactcgcccagggtgttttctcagggtgtttccg  
cgttccgggtcaaagttggcggtttattattatagtcagctgacgtgtagtgtattatacccggtgagttcctcaagaggccact  
cttgagtgcagcgagtagagtttctcctccgagccgctccgacaccgggactcgagtgttgacattgattattgactagta  
ttaatagtaataaattacggggtcattagttcatagcccatatatggagttccgcgttacataacttacggtaaatggcccgct  
ggctgaccgccaacgacccccgccattgacgtcaataatgacgtatgttcccatagtaacgccaatagggactttccatt  
gacgtcaatgggtggagttttacggtaaaactgccacttggcagtacatcaagtgtatcatatgccaagtacgccccctatt  
gacgtcaatgacggtaaatggcccgctggcattatgccagtacatgaccttatgggactttcctacttggcagtacatcta  
cgtattagtcacgctattaccatgggtgatgcggttttggcagtacatcaatgggcgtggatagcggtttgactcacggggatt  
tccaagtctccacccttggacgtcaatgggagtttgttttggcaccaaaatcaacgggactttccaaaatgtcgtacaactc  
cgccccattgacgcaaatgggcggtaggcggtgtacgggtgggaggtctatataagcagagctcgttttagtgaaccgtaagct  
tgatcttgggtggcgtaaaactcccgcacctcttcggccagcgccctttagaagcgcgatgggatctgactacaaagacgat  
gacgacaagggtatcctccgaggactccgcgggctcgccttgcgcgtcgggctccggctcggacaccgagaacacgcg  
gccccaggagaacacgttccccaaggcgagcccgatctgaagaaggagagcgaggaggacaagtccccgtgtgcat  
ccgcgaggcggtcagccaggtgctcaaaggctacgactggacgctgggtgcccatgccggtgcgcgtcaacggctccag  
caagaacaagccgcacgtcaagcgcccatgaacgccttcatggtgtgggcgcaggcggcgcgcaggaagctcgcgg  
accagtaccgcacttgcacaacgccgagctcagcaagacgctgggcaagctctggagacttctgaacgagagcgaga  
agcgggcccttctgtggaggaggcgggagcggtgcgcgtgcagcacaagaaggaccacccggattacaagtaccagccg  
cggcggagggaagtcggtgaagaacgggcagggcgaggagggccacggagcagacgcacatctccccaac  
gccatcttcaaggcgctgcaggccgactcaagcttgcacactcctcctccggcatgagcgaggtgcactccccggcga  
gcactcggggcaatcccaggggccaccgacccccaccacccccaaaaccgacgtgcagccgggcaaggctgacc  
tgaagcgagagggggcgcccccttgcagagggggggcagacagccccctatcgacttccgcgacgtggacatcggcgag  
ctgagcagcgacgtcatctccaacatcgagaccttcgatgtcaacgagtttgaccagtacctgccgccaacggccaccc  
gggggtgccggccacgcacggccaggtcacctacacgggcagctacggcatcagcagcaccgcgggccacccccggcg  
agcgcgggccacgtgtggatgtccaagcagcaggcgccgcccacccccgcagcagccccacaggccccgcgg  
ccccgcaggcgccccgcagccgcaggcgggcgccccacagcagccggcgccacccccgcagcagccacaggcg  
cacacgctgaccacgctgagcagcgagccgggccaagtcccagcgaacgcacatcaagacggagcagctgagccca  
gccactacagcgagcagcagcagcactcggcccaacagatcgctacagcccccttaacctcccacactacagccccctc  
ctaccgccccatcacccgctcacagtacgactacaccgaccaccagaactccagctcctactacagccacgcggcaggc  
cagggcaccggccttactccacctacacatgaaccccgctcagcgccccatgtacacccccatcgccgacacctct  
ggggtcccttccatcccgacacccacagccccagcactgggaacaacccgtctacacacagctcactcgaccttgaga  
attctttagtagggtttacttgccttaaaaaacctcccacacctccccctgaacctgaacataaaatgaatgcaattgtgtgt  
taacttgtttattgcagcttataatggttacaaataaagcaatagcatcacaaatttcacaaataaagcattttttactgcattct  
agttgtggttgcctaaactcatcaatgtatcttatcatgtctggatcatcgatccataacttcgtataatgtatgctatacgaagt  
atccagatctggttctatagtgtcacctaaatcgatgtgtatgatacataaggttatgtattaattgtagccgcttcaacgaca  
atatgtccataggggccctacgtcaccgccccgttcccacgccccgcgccacgtcacaaactccacccccctattatcata  
ttggcttcaatccaaaataagggtatatttattgatgtggcgagcgccccctggcgtaatagcgaagaggcccgccga  
tcgccccttcccaacagttgcgcagcctgaatggcgaatgggacgcgccctgtagcgggcgattaagcgcgggcggtgtg  
gtggttacgcgcagcgtgaccgctacacttgcagcgccctagcgcccgctccttgcgtttcttcccttcttctcgcacg  
ttcgccggcttccccgtcaagctctaaatcgggggctcccttaggggttcgatttagtgccttacggcacctcgaccccaa  
aaacttgattagggtgatggttcacgtagtgggcatcgccctgatagacggttttcgcccttgacgttggagtcacgttct  
ttaatagtggactcttgttccaaactgaacaacactcaaccctatctcggctctattcttttgattataagggttttgcgattc  
ggcctattggttaaaaaatgagctgatttaacaaaaatgaacgcgaatttaacaaaatattaacgcttacaatttaggtggca  
cttttcggggaaatgtgcgcggaaccctatttgtttattttctaaatacattcaaatatgtatccgctcatgagacaataaccct  
gataaatgcttcaataatattgaaaaaggaagagtatgagtattcaacatttccgtgtcgccttattccctttttgcggcattt






**Fig 11 continued:**

gccttcctgttttgctcaccagaaacgctggtgaaagtaaaagatgctgaagatcagttgggtgcacgagtgggttacatc  
gaactggatctcaacagcggtaagatccttgagagtttgcgccgaagaacgtttccaatgatgagcacttttaaagttctg  
ctatgtggcgcggtattatcccgtattgacgccgggcaagagcaactcggtcgccgcatacactattctcagaatgacttgg  
tgagtactcaccagtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgctgccataaccatgagt  
gataacactgcggccaacttacttctgacaacgatcggaggaccgaaggagctaaccgctttttgcacaacatgggggat  
catgtaactcgccttgatcgttgggaaccggagctgaatgaagccataccaaacgacgagcgtgacaccacgatgcctgt  
agcaatggcaacaacgttgcgcaaactattaactggcgaactacttactctagcttcccggcaacaattaatagactggatg  
gaggcggataaagttgcaggaccacttctgcgctcggcccttcggctggctggtttattgctgataaatctggagccggtg  
agcgtgggtctcgcggtatcattgcagcactggggccagatggtaagccctcccgatcgtagttatctacacgacgggga  
gtcaggcaactatggatgaacgaaatagacagatcgtgagataggtgcctcactgattaagcattggtaactgtcagacca  
agtttactcatatatacttttagattgatttaaaacttcatttttaatttaaaaggatctaggtgaagatccttttgataatctcatgac  
caaatcccttaacgtgagtttctgctccactgagcgtcagaccccgtagaaaagatcaaaggatcttcttgagatccttttttc  
tgcgcgtaatctgctgcttgcaacaaaaaaaccaccgctaccagcgggtggtttgttgccggatcaagagctaccaactctt  
ttccgaaggtaactggcttcagcagagcgcagataccaaatactgtccttctagtgtagccgtagttaggccaccacttcaa  
gaactctgtagcaccgcctacatacctcgtctgctaactctgttaccagtggctgctgccagtggcgataagtcgtgtcttac  
cgggttggtactcaagacgatagttaccggataaggcgcagcggctcgggctgaacggggggttcgtgcacacagcccag  
cttgagcgaacgacctacaccgaactgagatacctacagcgtgagctatgagaaagcggcacgcttcccgaagggaga  
aaggcggacaggtatccggtaagcggcagggctcggaaacaggagagcgcacgaggagcttccagggggaaacgcct  
ggtatctttatagtcctgtcgggtttcggcacctctgacttgagcgtcgattttgtgatgctcgtcaggggggcggagcctatg  
gaaaaacgccagcaacgcggccttttacgggttcctggccttttgctggccttttgctcacatgttcttctgcgttatccctg  
attctgtggataaccgtattaccgcctttgagtgagctgataccgctcggcgagccgaacgaccgagcgcagcagtcag  
tgagcgaggaagcgggaagagcgcccaatacgcaaaccgcctctccccgcgcgttggccgattcattaatgcagggggcc  
gctgcggc


**SEQ ID No. 1**



**FIG. 12**



**FIG. 13**





**FIG. 14**

